CEO Raman Mehta said Alchemlife was built on Western scientific accountability but has not abandoned its Ayurvedic roots. Speaking with NutraIngredients-USA at the Expo West trade show in Anaheim, CA Mehta said that Ayurveda has stood the test of time, even if some of its principles are hard fit into the Western scientific model.
“These traditional medicine systems have been very successful. That’s why they’ve lasted so long. But with modern times people are wanting a more direct accountability for the product,” Mehta said.
Alchemlife has flown under the radar as far as the US market is concerned. But the company has a long history in India and now bills itself as India’s largest manufacturer of phytonutrient-based Active Pharmaceutical Ingredients. The company calls its proprietary extraction technology Phytoplex, and its extraction facility has a capacity of 6,500 tons annually. The company says its ingredients can be found in finished products in the US, Europe and Asia. The company says its facilities have been inspected by FDA, the World Health Organization and the French Agence Francaise de Securite Sanitaire des Produits de Sante.
Alchemlife, which was founded in 1984, is taking a new tack with the release of three finished product formulas. They are:
- Liverubin, which features what the company says is the first highly water-soluble silymarin (extracted from milk thistle) to support liver function.
- FlexiQule, which is a blend of concentrated Boswellia serrata (Indian frankincense) and ginger. It is aimed at the joint health market.
- PhytoRelief, a lozenge aimed at cold and flu sufferers that features pomegranate extract, turmeric and ginger.
“We are supplementing the existing system of medicine. My belief is that we have to do our best to deriving the best of natural medicines worldwide. The population is aging, and existing medical systems won’t sustain us long without side effects,” Mehta said.
Mehta said the new products will be on the market within three months. The company has a further five formulas in near-term development, he said.